‘I think this is the best data we have so far’ supporting the use of apixaban in the especially high-risk population with atrial fibrillation, the lead researcher concludes. A randomized trial is forthcoming.
Medscape Medical News
This post was syndicated from Medscape Medical News Headlines. Click here to read the full text on the original website.